Neurocrine Biosciences, Inc. – Product Pipeline Review – Q4 2010

Date: December 1, 2010
Pages: 65
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: N4FEED41CA2EN
Leaflet:

Download PDF Leaflet

Neurocrine Biosciences, Inc. – Product Pipeline Review – Q4 2010
Neurocrine Biosciences, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Neurocrine Biosciences, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Neurocrine Biosciences, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Neurocrine Biosciences, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Neurocrine Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Neurocrine Biosciences, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Neurocrine Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Neurocrine Biosciences, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Neurocrine Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Neurocrine Biosciences, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Neurocrine Biosciences, Inc. and identify potential opportunities in those areas.
Neurocrine Biosciences, Inc. Snapshot
Neurocrine Biosciences, Inc. Overview
Key Information
Key Facts
Neurocrine Biosciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Neurocrine Biosciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Neurocrine Biosciences, Inc. – Pipeline Products Glance
Neurocrine Biosciences, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Neurocrine Biosciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Neurocrine Biosciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Neurocrine Biosciences, Inc. – Drug Profiles
Indiplon
  Product Description
  Mechanism of Action
  R&D Progress
Elagolix
  Product Description
  Mechanism of Action
  R&D Progress
Elagolix
  Product Description
  Mechanism of Action
  R&D Progress
NBI-6024
  Product Description
  Mechanism of Action
  R&D Progress
Urocortin 2
  Product Description
  Mechanism of Action
  R&D Progress
Elagolix
  Product Description
  Mechanism of Action
  R&D Progress
Interleukin-4 PE38KDEL Cytotoxin
  Product Description
  Mechanism of Action
  R&D Progress
NBI-98854
  Product Description
  Mechanism of Action
  R&D Progress
AEDs
  Product Description
  Mechanism of Action
  R&D Progress
GnRH Antagonists
  Product Description
  Mechanism of Action
  R&D Progress
Glucose Dependent Insulin Secretagogues
  Product Description
  Mechanism of Action
  R&D Progress
Neurocrine Biosciences, Inc. – Pipeline Analysis
Neurocrine Biosciences, Inc. – Pipeline Products by Therapeutic Class
Neurocrine Biosciences, Inc. Pipeline Products By Target
Neurocrine Biosciences, Inc. – Pipeline Products by Route of Administration
Neurocrine Biosciences, Inc. – Pipeline Products by Molecule Type
Neurocrine Biosciences, Inc. – Recent Pipeline Updates
Neurocrine Biosciences, Inc. - Dormant Projects
Neurocrine Biosciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NBI-5788
R121919
Neurocrine Biosciences, Inc. – Company Statement
Neurocrine Biosciences, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 22, 2010: Neurocrine Biosciences Successfully Completes Phase II Daisy PETAL Study With Elagolix
Oct 18, 2010: Neurocrine Completes Reports Second Phase I Clinical Trial Of NBI-98854
May 24, 2010: Neurocrine Biosciences Announces Positive Results From Daisy PETAL Study Of Elagolix
Apr 13, 2010: Neurocrine Biosciences Announces The Initiation Of Second VMAT2 Phase I Clinical Trial
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
Dec 21, 2009: Neurocrine Announces VMAT2 Inhibitor Phase I Single Ascending Dose Study Desired Pharmacokinetic Profile
Financial Deals Landscape
Neurocrine Biosciences, Inc., Deals Volume Summary, 2004 to YTD 2010
Neurocrine Biosciences, Inc., Deals Summary By Region, 2004 to YTD 2010
Neurocrine Biosciences, Inc., Deals Summary, 2004 to YTD 2010
Neurocrine Biosciences, Inc. Detailed Deal Summary
Asset Purchase
Protox Therapeutics Acquires Assets From Neurocrine
Equity Offering
Neurocrine Completes Private Placement Of $10 Million
Neurocrine Announces Private Placement Of $75 Million
Pharmacopeia Drug Discovery Expands Its Agreement With Neurocrine Biosciences
Licensing Agreements
Neurocrine Biosciences Enters Into Licensing Agreement With Dainippon Sumitomo Pharma
Neurocrine Biosciences Enters Into Licensing Agreement With Yissum Research Development Company
Neurocrine Biosciences Enters into Licensing Agreement With Almirall Prodesfarma
Neurocrine Biosciences and Pfizer Terminate Collaboration Agreement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Neurocrine Biosciences, Inc. – Pipeline by Therapy Area and Indication, 2010
Neurocrine Biosciences, Inc. – Pipeline by Stage of Development, 2010
Neurocrine Biosciences, Inc. – Monotherapy Products in Pipeline, 2010
Neurocrine Biosciences, Inc. – Filed, 2010
Neurocrine Biosciences, Inc. – Phase III, 2010
Neurocrine Biosciences, Inc. - Phase II, 2010
Neurocrine Biosciences, Inc. - Phase I, 2010
Neurocrine Biosciences, Inc. - Pipeline By Therapeutic Class, 2010
Neurocrine Biosciences, Inc. - Pipeline By Target, 2010
Neurocrine Biosciences, Inc. – Pipeline By Route of Administration, 2010
Neurocrine Biosciences, Inc. – Pipeline By Molecule Type, 2010
Neurocrine Biosciences, Inc. – Recent Pipeline Updates, 2010
Neurocrine Biosciences, Inc. - Dormant Developmental Projects, 2010
Neurocrine Biosciences, Inc. - Discontinued Pipeline Products, 2010
Neurocrine Biosciences, Inc., Deals Summary, 2004 to YTD 2010
Neurocrine Biosciences, Inc., Deals Summary by Region, 2004 to YTD 2010
Neurocrine Biosciences, Inc., Deals Summary, 2004 to YTD 2010 51

LIST OF FIGURES

Neurocrine Biosciences, Inc. – Pipeline by Therapy Area and Indication, 2010
Neurocrine Biosciences, Inc. – Pipeline by Stage of Development, 2010
Neurocrine Biosciences, Inc. – Monotherapy Products in Pipeline, 2010
Neurocrine Biosciences, Inc. – Pipeline By Therapeutic Class, 2010
Neurocrine Biosciences, Inc. - Pipeline By Target, 2010
Neurocrine Biosciences, Inc. – Pipeline By Route of Administration, 2010
Neurocrine Biosciences, Inc. – Pipeline By Molecule Type, 2010 34

Ask Your Question

Neurocrine Biosciences, Inc. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: